Even in the midst of FDA warnings and mass tort litigation, Johnson & Johnson’s prescription drug manufacturer Janssen Pharmaceutical continues …
Deep vein thrombosis is a common type of clot that people develop, mostly in the lower leg or thigh.
Under the health care category, the FDA helps monitor and test drugs and medical devices for safety.
Drugs and medications are meant to heal our bodies, not harm them.
A recent study conducted on new blood thinners and their potential gastrointestinal bleeding risks found that Xarelto (clinically known as rivaroxaban) and Pradaxa (dabigatran) could be more dangerous than warfarin.
This May, Xarelto drug makers Bayer and Johnson & Johnson obtained permission from the Ministerio de Salud (or the Ministry of Health) to market the product in Costa Rica.
Texas woman Lola Daniel is suing drug companies Janssen and Bayer for injuries she suffered while taking blood thinner Xarelto, seeking $4.5 million in damages.
Bayer and Johnson & Johnson are now pushing the Food and Drug Administration for another Xarelto indication in hopes of securing an even stronger spot in the anticoagulant market.
Xarelto is a blood thinner, or anticoagulant, that’s prescribed to help prevent heart attacks in people who are at risk, but it also carries the possible side effect of internal bleeding that often leads to hospitalization.
There has been a lot of talk in the news lately of the blood thinner Xarelto and the growing number of lawsuits the manufacturers of this anticoagulant are facing.